Impact Biomedical

Impact Biomedical ROIC

The Return on Invested Capital (ROIC) of Impact Biomedical (IBO) as of Nov 17, 2026 is -89.48 %. In the previous year, Return on Invested Capital (ROIC) was -188.08 % — a change of -52.43% (higher).

ROIC

-89.48 %

YoY

-52.43%

Last updated:

Return on Invested Capital (ROIC) of Impact Biomedical is 2025 -89.48 % . Return on Invested Capital (ROIC) of Impact Biomedical was 2024 -188.08 % . It decreases by -52.43% higher compared to the previous year.

The Impact Biomedical ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
-49.77 USD
Jan 1, 2019
-621.85 USD
Jan 1, 2020
-1.53 USD
Jan 1, 2021
-14.35 USD
Jan 1, 2022
-17.83 USD
Jan 1, 2023
-11.63 USD
Jan 1, 2024
-188.08 USD
Jan 1, 2025
-89.48 USD
The Impact Biomedical ROIC history
YEARROICYoY
-89.48 %-52.43%
-188.08 %+1,517.76%
-11.63 %-34.79%
-17.83 %+24.23%
-14.35 %+836.27%
-1.53 %-99.75%
-621.85 %+1,149.39%
-49.77 %-64.01%
-138.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Impact Biomedical Stock analysis

What does Impact Biomedical do? Impact Biomedical Inc generates revenue through its subsidiary Global BioLife, Inc., which develops products like the Linebacker project for universal therapeutic drugs, Laetose as a sugar substitute, 3F (Functional Fragrance Formulation) for mosquito repellent, and Equivir/Nemovir antimicrobial medication. The company focuses on neurological, oncological, and immune-related disease treatments, alongside open-air defense initiatives targeting airborne diseases such as tuberculosis and influenza. DSS, Inc. owns Impact Biomedical as a wholly owned subsidiary, leveraging its intellectual property for drug discovery and biomedical advancements. The primary buyers of Impact Biomedical's products include healthcare providers and consumers interested in innovative treatments for neurological, oncological, and immune conditions. Open-air defense solutions are targeted at public health organizations seeking to curb airborne disease transmission. The Linebacker project and Equivir/Nemovir are positioned for pharmaceutical and medical markets, while 3F and Laetose cater to consumer and wellness sectors. Global BioLife, Inc. drives product development across four key areas, with Linebacker focusing on therapeutic platforms, Laetose serving as a dietary alternative, 3F targeting insect repellent needs, and Equivir/Nemovir addressing antimicrobial requirements. These products align with the company's mission to advance drug discovery and prevention in bio health and biomedical fields. Impact Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Impact Biomedical stock

Return on Invested Capital (ROIC) of Impact Biomedical is -89.48 % in 2025.

Return on Invested Capital (ROIC) of Impact Biomedical changed from -188.08 % to -89.48 %, representing a -52.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Impact Biomedical since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Impact Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Impact Biomedical

All Key Metrics — Impact Biomedical